Search Within

Terry Kheng Pak

Formats
  1. Journal Article (6)
  2. Meeting Abstract (5)
  3. Review (1)
Groups
  1. Clinical Pharmacy Specialists (11)
  2. Department of Medicine (11)
  3. Center for Hematologic Malignancies (7)
  4. Epidemiology and Biostatistics (7)
  5. Hematologic Malignancies, Division of (7)
  6. Lymphoma (7)

More Groups

People
  1. Michael Buege (8)
  2. Phuong Dao (7)
  3. Andrea Levoir (6)
  4. Dazhi Liu (5)
  5. Josiah Land (5)
  6. Tim Peterson (5)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (4)
  4. 2020 (2)
  5. 2019 (2)
  6. 2018 (1)
Publications
  1. Blood (2)
  2. Annals of Pharmacotherapy (1)
  3. British Journal of Cancer (1)
  4. Clinical Lymphoma, Myeloma and Leukemia (1)
  5. European Journal of Haematology (1)
  6. Hematological Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. American Society of Hematology (2)
  3. Elsevier Inc. (2)
  4. John Wiley & Sons (1)
  5. Nature Publishing Group (1)
  6. Sage Publications (1)

More Publishers

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure
    Journal Article

    Buege, M. J.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Dao, P. H.; Matasar, M. J.
    European Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers
    Journal Article

    Murciano-Goroff, Y. R.; Pak, T.; Mondaca, S.; Flynn, J. R.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Plodkowski, A. J.; Wu, S. L.; Kris, M. G.; more...
    British Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Journal Article

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City
    Journal Article

    Yerram, P.; Thackray, J.; Modelevsky, L. R.; Land, J. D.; Reiss, S. N.; Spatz, K. H.; Levoir, A. C.; Pak, T. K.; Dao, P. H.; Buege, M. J.; more...
    Journal of Oncology Pharmacy Practice (2021)

    Fulltext@MSK | Save
  • IVAC +/- R for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A. C.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Blood (2020)

    Fulltext@MSK | Save
  • Management of mantle cell lymphoma in the era of novel oral agents
    Review

    Buege, M. J.; Kumar, A.; Dixon, B. N.; Tang, L. A.; Pak, T.; Orozco, J.; Peterson, T. J.; Maples, K. T.
    Annals of Pharmacotherapy (2020)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save